Matinas BioPharma Hldgs Analyst Ratings
Matinas BioPharma Hldgs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/31/2023 | 412.38% | HC Wainwright & Co. | → $3 | Reiterates | → Buy |
| 08/13/2020 | 497.78% | Aegis Capital | $3.25 → $3.5 | Maintains | Buy |
| 01/27/2020 | 412.38% | Piper Sandler | → $3 | Initiates Coverage On | → Overweight |
| 01/24/2020 | 412.38% | SunTrust Robinson Humphrey | → $3 | Initiates Coverage On | → Buy |
| 06/26/2019 | 583.18% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
| 05/17/2019 | 753.97% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 02/11/2019 | — | Roth Capital | Initiates Coverage On | → Buy | |
| 11/13/2018 | 753.97% | Maxim Group | $2 → $5 | Maintains | Buy |
| 08/13/2018 | 241.59% | Maxim Group | $3 → $2 | Maintains | Buy |
| 07/10/2018 | 412.38% | Maxim Group | $4 → $3 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年1月31日 | 412.38% | HC Wainwright公司 | →$3 | 重申 | →購買 |
| 2020年08月13日 | 497.78% | 宙斯盾資本 | $3.25→$3.5 | 維護 | 買 |
| 2020/01/27 | 412.38% | 派珀·桑德勒 | →$3 | 開始承保 | →超重 |
| 1/24/2020 | 412.38% | SunTrust Robinson Humphrey | →$3 | 開始承保 | →購買 |
| 2019年06月26日 | 583.18% | HC Wainwright公司 | →$4 | 開始承保 | →購買 |
| 2019年05月17日 | 753.97% | BTIG | →$5 | 開始承保 | →購買 |
| 2019年02月11日 | - | 羅斯資本 | 開始承保 | →購買 | |
| 2018年11月13日 | 753.97% | Maxim集團 | $2→$5 | 維護 | 買 |
| 2018年08月13日 | 241.59% | Maxim集團 | $3→$2 | 維護 | 買 |
| 2018年07月10日 | 412.38% | Maxim集團 | $4→$3 | 維護 | 買 |
What is the target price for Matinas BioPharma Hldgs (MTNB)?
Matinas BioPharma Hldgs(MTNB)的目標價格是多少？
The latest price target for Matinas BioPharma Hldgs (AMEX: MTNB) was reported by HC Wainwright & Co. on January 31, 2023. The analyst firm set a price target for $3.00 expecting MTNB to rise to within 12 months (a possible 412.38% upside). 1 analyst firms have reported ratings in the last year.
HC Wainwright&Co.於2023年1月31日報道了Matinas BioPharma Hldgs(美國證券交易所代碼：MTNB)的最新目標價。這家分析公司將目標價定為3美元，預計MTNB將在12個月內上漲至(可能上漲412.38%)。1家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Matinas BioPharma Hldgs (MTNB)?
Matinas BioPharma Hldgs(MTNB)的最新分析師評級是多少？
The latest analyst rating for Matinas BioPharma Hldgs (AMEX: MTNB) was provided by HC Wainwright & Co., and Matinas BioPharma Hldgs reiterated their buy rating.
Matinas BioPharma Hldgs(美國證券交易所代碼：MTNB)的最新分析師評級由HC Wainwright&Co.提供，Matinas BioPharma Hldgs重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Matinas BioPharma Hldgs (MTNB)?
Matinas BioPharma Hldgs(MTNB)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Matinas BioPharma Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Matinas BioPharma Hldgs was filed on January 31, 2023 so you should expect the next rating to be made available sometime around January 31, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公開財務報表，與Matinas BioPharma Hldgs的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Matinas BioPharma Hldgs的最後一次評級是在2023年1月31日提交的，所以你應該預計下一次評級將在2024年1月31日左右的某個時候提供。
Is the Analyst Rating Matinas BioPharma Hldgs (MTNB) correct?
分析師對Matinas BioPharma Hldgs(MTNB)的評級正確嗎？
While ratings are subjective and will change, the latest Matinas BioPharma Hldgs (MTNB) rating was a reiterated with a price target of $0.00 to $3.00. The current price Matinas BioPharma Hldgs (MTNB) is trading at is $0.59, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Matinas BioPharma Hldgs(MTNB)評級重申，目標價在0.00美元至3.00美元之間。Matinas BioPharma Hldgs(MTNB)目前的交易價格為0.59美元，在分析師的預測範圍內。